Drug intelligence / Profile preview

LNP-LASSAsaRNA-01

Development stage: Unknown
Lead developer: Imperial College London
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

LNP-LASSAsaRNA-01 is an investigational self-amplifying RNA (saRNA) vaccine candidate designed to prevent Lassa fever. Developed by Imperial College London, the vaccine is delivered via lipid nanoparticles (LNPs) and targets the glycoprotein of the Lassa virus (LASV). It is being evaluated in the EML-Vac first-in-human Phase I clinical trial alongside companion vaccines targeting Ebola (LNP-EBOVsaRNA-01) and Marburg (LNP-MARVsaRNA-01) viruses. The vaccine is designed to instruct host cells to produce the Lassa virus glycoprotein, thereby stimulating a protective immune response.

Targets

GPC (Lassa virus glycoprotein complex)

Beyond the preview

Go deeper on LNP-LASSAsaRNA-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNP-LASSAsaRNA-01.

Explore the full profile